Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors

  • Djurec, Magdolna
  • Graña, Osvaldo
  • Lee, Albert
  • Troulé, Kevin
  • Espinet, Elisa
  • Cabras, Lavinia
  • Navas, Carolina
  • Blasco, María Teresa
  • Martín-Díaz, Laura
  • Burdiel, Miranda
  • Li, Jing
  • Liu, Zhaoqi
  • Vallespinós, Mireia
  • Sanchez-Bueno, Francisco
  • Sprick, Martin R.
  • Trumpp, Andreas
  • Sainz, Bruno
  • Al-Shahrour, Fátima
  • Rabadan, Raul
  • Guerra, Carmen
  • Barbacid, Mariano
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the presence of abundant desmoplastic stroma primarily composed of cancer-associated fibroblasts (CAFs). It is generally accepted that CAFs stimulate tumor progression and might be implicated in drug resistance and immunosuppression. Here, we have compared the transcriptional profile of PDGFRα + CAFs isolated from genetically engineered mouse PDAC tumors with that of normal pancreatic fibroblasts to identify genes potentially implicated in their protumorigenic properties. We report that the most differentially expressed gene, Saa3, a member of the serum amyloid A (SAA) apolipoprotein family, is a key mediator of the protumorigenic activity of PDGFRα + CAFs. Whereas Saa3-competent CAFs stimulate the growth of tumor cells in an orthotopic model, Saa3-null CAFs inhibit tumor growth. Saa3 also plays a role in the cross talk between CAFs and tumor cells. Ablation of Saa3 in pancreatic tumor cells makes them insensitive to the inhibitory effect of Saa3-null CAFs. As a consequence, germline ablation of Saa3 does not prevent PDAC development in mice. The protumorigenic activity of Saa3 in CAFs is mediated by Mpp6, a member of the palmitoylated membrane protein subfamily of the peripheral membrane-associated guanylate kinases (MAGUK). Finally, we interrogated whether these observations could be translated to a human scenario. Indeed, SAA1, the ortholog of murine Saa3, is overexpressed in human CAFs. Moreover, high levels of SAA1 in the stromal component correlate with worse survival. These findings support the concept that selective inhibition of SAA1 in CAFs may provide potential therapeutic benefit to PDAC patients., This work was supported by European Research Council Grants ERC-AG/250297-RAS AHEAD and ERC-AG/695566-THERACAN, Spanish Ministry of Economy and Competitiveness Grant SAF2014-59864-R, and Asociación Española contra el Cáncer Grant GC16173694BARB (to M. Barbacid). M.D. was supported by a fellowship from La Caixa International Fellowship Program. M. Barbacid is the recipient of an Endowed Chair from the AXA Research Fund
Repisalud
Publicación Artículo científico (JournalArticle)

The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer

  • Simón-Carrasco, Lucía
  • Jiménez, Gerardo
  • Barbacid, Mariano
  • Drosten, Matthias
The transcriptional repressor Capicua (CIC) has emerged as an important rheostat of cell growth regulated by RAS/MAPK signaling. Cic was originally discovered in Drosophila, where it was shown to be inactivated by MAPK signaling downstream of the RTKs Torso and EGFR, which results in signal-dependent responses that are required for normal cell fate specification, proliferation and survival of developing and adult tissues. CIC is highly conserved in mammals, where it is also negatively regulated by MAPK signaling. Here, we review the roles of CIC during mammalian development, tissue homeostasis, tumor formation and therapy resistance. Available data indicate that CIC is involved in multiple biological processes, including lung development, liver homeostasis, autoimmunity and neurobehavioral processes. Moreover, CIC has been shown to be involved in tumor development as a tumor suppressor, both in human as well as in mouse models. Finally, several lines of evidence implicate CIC as a determinant of sensitivity to EGFR and MAPK pathway inhibitors, suggesting that CIC may play a broader role in human cancer than originally anticipated.
Repisalud
Publicación Artículo científico (JournalArticle)

KRAS inhibitors: going noncovalent.

  • Drosten, Matthias
  • Barbacid, Mariano
KRASG12D is the most frequent KRAS mutation in human cancer with particularly high frequencies in pancreatic and colorectal cancer. Informed by the structure of the KRASG12C inhibitor adagrasib, Hallin et al. have now, through multiple rounds of structure-based drug design, identified and validated a potent, selective, and noncovalent KRASG12D inhibitor, MRTX1133. This study demonstrated that MRTX1133 inhibited both the inactive and active state of KRASG12D and showed potent antitumor activity in several preclinical models of pancreatic and colorectal cancer, especially when combined with cetuximab, a monoclonal antibody against the EGFR, or BYL-719, a potent PI3Kα inhibitor.
Repisalud
Publicación Artículo científico (JournalArticle)

Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors

  • Djurec, Magdolna
  • Graña Castro, Osvaldo
  • Lee, Albert
  • Troulé, Kevin
  • Espinet, Elisa
  • Cabras, Lavinia
  • Navas, Carolina
  • Blasco, María Teresa
  • Martín-Díaz, Laura
  • Burdiel, Miranda
  • Li, Jing
  • Liu, Zhaoqi
  • Vallespinós, Mireia
  • Sanchez-Bueno, Francisco
  • Sprick, Martin R
  • Trumpp, Andreas
  • Sainz, Bruno
  • Al-Shahrour, Fatima
  • Rabadan, Raul
  • Guerra, Carmen
  • Barbacid, Mariano
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the presence of abundant desmoplastic stroma primarily composed of cancer-associated fibroblasts (CAFs). It is generally accepted that CAFs stimulate tumor progression and might be implicated in drug resistance and immunosuppression. Here, we have compared the transcriptional profile of PDGFRα+ CAFs isolated from genetically engineered mouse PDAC tumors with that of normal pancreatic fibroblasts to identify genes potentially implicated in their protumorigenic properties. We report that the most differentially expressed gene, Saa3, a member of the serum amyloid A (SAA) apolipoprotein family, is a key mediator of the protumorigenic activity of PDGFRα+ CAFs. Whereas Saa3-competent CAFs stimulate the growth of tumor cells in an orthotopic model, Saa3-null CAFs inhibit tumor growth. Saa3 also plays a role in the cross talk between CAFs and tumor cells. Ablation of Saa3 in pancreatic tumor cells makes them insensitive to the inhibitory effect of Saa3-null CAFs. As a consequence, germline ablation of Saa3 does not prevent PDAC development in mice. The protumorigenic activity of Saa3 in CAFs is mediated by Mpp6, a member of the palmitoylated membrane protein subfamily of the peripheral membrane-associated guanylate kinases (MAGUK). Finally, we interrogated whether these observations could be translated to a human scenario. Indeed, SAA1, the ortholog of murine Saa3, is overexpressed in human CAFs. Moreover, high levels of SAA1 in the stromal component correlate with worse survival. These findings support the concept that selective inhibition of SAA1 in CAFs may provide potential therapeutic benefit to PDAC patients.
Repisalud
Publicación Artículo científico (JournalArticle)

Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.

  • Blasco, María Teresa
  • Navas, Carolina
  • Martín-Serrano, Guillermo
  • Martín-Díaz, Laura
  • Li, Jing
  • Morales-Cacho, Lucia
  • Esteban-Burgos, Laura
  • Perales-Patón, Javier
  • Bousquet-Mur, Emilie
  • Castellano, Eva
  • Jacob, Harrys K C
  • Cabras, Lavinia
  • Sainz, Bruno
  • Dusetti, Nelson
  • Iovanna, Juan
  • Sánchez-Bueno, Francisco
  • Hidalgo, Manuel
  • Khiabanian, Hossein
  • Rabadán, Raul
  • Graña Castro, Osvaldo
  • Lechuga C, Lechuga CG
  • Djurec M, Djurec M
  • Musteanu, Mónica
  • Drosten, Matthias
  • Ortega Jimenez, Sagrario
  • Mulero, Francisca
  • Guerra, Carmen
  • Barbacid, Mariano
  • Al-Shahrour, Fatima
Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7% due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c-RAF expression results in complete regression of a significant percentage of PDAC tumors driven by Kras/Trp53 mutations in genetically engineered mice. Moreover, systemic elimination of these targets induces toxicities that are well tolerated. Response to this targeted therapy correlates with transcriptional profiles that resemble those observed in human PDACs. Finally, inhibition of EGFR and c-RAF expression effectively blocked tumor progression in nine independent patient-derived xenografts carrying KRAS and TP53 mutations. These results open the door to the development of targeted therapies for PDAC patients.
Repisalud
Publicación Artículo científico (JournalArticle)

Targeting KRAS mutant lung cancer: light at the end of the tunnel.

  • Drosten, Matthias
  • Barbacid, Mariano
For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies based on personalized medicine owing to the complexity of designing inhibitors to selectively target KRAS and downstream targets with acceptable toxicities. The recent development of selective KRASG12C inhibitors represents a landmark after 40 years of intense research efforts since the identification of KRAS as a human oncogene. Here, we discuss the mechanisms responsible for the rapid development of resistance to these inhibitors, as well as potential strategies to overcome this limitation. Other therapeutic strategies aimed at inhibiting KRAS oncogenic signaling by targeting either upstream activators or downstream effectors are also reviewed. Finally, we discuss the effect of targeting the mitogen-activated protein kinase (MAPK) pathway, both based on the failure of MEK and ERK inhibitors in clinical trials, as well as on the recent identification of RAF1 as a potential target due to its MAPK-independent activity. These new developments, taken together, are likely to open new avenues to effectively treat KRAS mutant LUAD.
Repisalud
Publicación Artículo científico (JournalArticle)

KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.

  • Salmón, Marina
  • Paniagua, Guillem
  • Fernández-García, Fernando
  • Zarzuela, Eduardo
  • Álvarez-Díaz, Ruth
  • Musteanu, Mónica
  • Muñoz, Javier
  • Drosten, Matthias
  • Lechuga, Carmen G
  • Guerra, Carmen
  • Caleiras, E
  • Ortega Jimenez, Sagrario
  • Barbacid, Mariano
In mammals, the KRAS locus encodes two protein isoforms, KRAS4A and KRAS4B, which differ only in their C terminus via alternative splicing of distinct fourth exons. Previous studies have shown that whereas KRAS expression is essential for mouse development, the KRAS4A isoform is expendable. Here, we have generated a mouse strain that carries a terminator codon in exon 4B that leads to the expression of an unstable KRAS4B154 truncated polypeptide, hence resulting in a bona fide Kras4B-null allele. In contrast, this terminator codon leaves expression of the KRAS4A isoform unaffected. Mice selectively lacking KRAS4B expression developed to term but died perinatally because of hypertrabeculation of the ventricular wall, a defect reminiscent of that observed in embryos lacking the Kras locus. Mouse embryonic fibroblasts (MEFs) obtained from Kras4B-/- embryos proliferated less than did wild-type MEFs, because of limited expression of KRAS4A, a defect that can be compensated for by ectopic expression of this isoform. Introduction of the same terminator codon into a Kras FSFG12V allele allowed expression of an endogenous KRAS4AG12V oncogenic isoform in the absence of KRAS4B. Exposure of Kras +/FSF4AG12V4B- mice to Adeno-FLPo particles induced lung tumors with complete penetrance, albeit with increased latencies as compared with control Kras +/FSFG12V animals. Moreover, a significant percentage of these mice developed proximal metastasis, a feature seldom observed in mice expressing both mutant isoforms. These results illustrate that expression of the KRAS4AG12V mutant isoform is sufficient to induce lung tumors, thus suggesting that selective targeting of the KRAS4BG12V oncoprotein may not have significant therapeutic consequences.
Repisalud
Publicación Artículo científico (JournalArticle)

Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF

  • Blasco, María Teresa
  • Navas, Carolina
  • Martín-Serrano, Guillermo
  • Graña Castro, Osvaldo
  • Lechuga, Carmen G
  • Martín-Díaz, Laura
  • Djurec, Magdolna
  • Li, Jing
  • Morales-Cacho, Lucia
  • Esteban-Burgos, Laura
  • Perales-Patón, Javier
  • Bousquet-Mur, Emilie
  • Castellano, Eva
  • Jacob, Harrys K C
  • Cabras, Lavinia
  • Musteanu, Mónica
  • Drosten, Matthias
  • Ortega, Sagrario
  • Mulero, Francisca
  • Sainz, Bruno
  • Dusetti, Nelson
  • Iovanna, Juan
  • Sanchez-Bueno, Francisco
  • Hidalgo, Manuel
  • Khiabanian, Hossein
  • Rabadan, Raul
  • Al-Shahrour, Fatima
  • Guerra, Carmen
  • Barbacid, Mariano
Five-year survival for pancreatic ductal adenocarcinoma (PDAC) patients remains below 7% due to the lack of effective treatments. Here, we report that combined ablation of EGFR and c-RAF expression results in complete regression of a significant percentage of PDAC tumors driven by Kras/Trp53 mutations in genetically engineered mice. Moreover, systemic elimination of these targets induces toxicities that are well tolerated. Response to this targeted therapy correlates with transcriptional profiles that resemble those observed in human PDACs. Finally, inhibition of EGFR and c-RAF expression effectively blocked tumor progression in nine independent patient-derived xenografts carrying KRAS and TP53 mutations. These results open the door to the development of targeted therapies for PDAC patients.
Repisalud
Publicación Artículo científico (JournalArticle)

Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation.

  • García-Alonso, Sara
  • Mesa, Pablo
  • Ovejero, Laura de la Puente
  • Aizpurua, Gonzalo
  • Lechuga, Carmen G
  • Zarzuela, Eduardo
  • Santiveri, Clara M
  • Sanclemente, Manuel
  • Muñoz, Javier
  • Musteanu, Mónica
  • Campos-Olivas, Ramón
  • Martínez-Torrecuadrada, Jorge
  • Barbacid, Mariano
  • Montoya, Guillermo
RAF kinases are RAS-activated enzymes that initiate signaling through the MAPK cascade to control cellular proliferation, differentiation, and survival. Here, we describe the structure of the full-length RAF1 protein in complex with HSP90 and CDC37 obtained by cryoelectron microscopy. The reconstruction reveals a RAF1 kinase with an unfolded N-lobe separated from its C-lobe. The hydrophobic core of the N-lobe is trapped in the HSP90 dimer, while CDC37 wraps around the chaperone and interacts with the N- and C-lobes of the kinase. The structure indicates how CDC37 can discriminate between the different members of the RAF family. Our structural analysis also reveals that the folded RAF1 assembles with 14-3-3 dimers, suggesting that after folding RAF1 follows a similar activation as B-RAF. Finally, disruption of the interaction between CDC37 and the DFG segment of RAF1 unveils potential vulnerabilities in attempting the pharmacological degradation of RAF1 for therapeutic purposes.
Repisalud
Publicación Artículo científico (JournalArticle)

c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.

  • Sanclemente, Manuel
  • Francoz, Sarah
  • Esteban-Burgos, Laura
  • Bousquet-Mur, Emilie
  • Djurec, Magdolna
  • Lopez-Casas, Pedro P
  • Hidalgo, Manuel
  • Guerra, Carmen
  • Barbacid, Mariano
  • Musteanu, Mónica
  • Drosten, Matthias
A quarter of all solid tumors harbor KRAS oncogenes. Yet, no selective drugs have been approved to treat these malignancies. Genetic interrogation of the MAPK pathway revealed that systemic ablation of MEK or ERK kinases in adult mice prevent tumor development but are unacceptably toxic. Here, we demonstrate that ablation of c-RAF expression in advanced tumors driven by KrasG12V/Trp53 mutations leads to significant tumor regression with no detectable appearance of resistance mechanisms. Tumor regression results from massive apoptosis. Importantly, systemic abrogation of c-RAF expression does not inhibit canonical MAPK signaling, hence, resulting in limited toxicities. These results are of significant relevance for the design of therapeutic strategies to treat K-RAS mutant cancers.
Repisalud
Publicación Artículo científico (JournalArticle)

Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.

  • Wang, Haiyun
  • Nieto, Patricia
  • Zheng, Jie
  • Gómez-López, Gonzalo
  • Fernández-García, Fernando
  • Sanclemente, Manuel
  • Drosten, Matthias
  • Galán, Javier
  • Fajas, Lluis
  • Peng, Sheng-Bin
  • Santamaria, David
  • Musteanu, Mónica
  • Esteban-Burgos, Laura
  • Blanco-Aparicio, Carmen
  • Varela Bustos, Carmen
  • Guerra, Carmen
  • Caleiras, E
  • Martinez Torrecuadrada, Jorge Luis
  • Barbacid, Mariano
  • Caleiras, Eduardo
  • Martínez-Torrecuadrada, Jorge
KRAS mutant lung adenocarcinomas remain intractable for targeted therapies. Genetic interrogation of KRAS downstream effectors, including the MAPK pathway and the interphase CDKs, identified CDK4 and RAF1 as the only targets whose genetic inactivation induces therapeutic responses without causing unacceptable toxicities. Concomitant CDK4 inactivation and RAF1 ablation prevented tumor progression and induced complete regression in 25% of KRAS/p53-driven advanced lung tumors, yet a significant percentage of those tumors that underwent partial regression retained a population of CDK4/RAF1-resistant cells. Characterization of these cells revealed two independent resistance mechanisms implicating hypermethylation of several tumor suppressors and increased PI3K activity. Importantly, these CDK4/RAF1-resistant cells can be pharmacologically controlled. These studies open the door to new therapeutic strategies to treat KRAS mutant lung cancer, including resistant tumors.
Repisalud
Publicación Artículo científico (JournalArticle)

The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer.

  • Simón-Carrasco, Lucía
  • Jiménez, Gerardo
  • Barbacid, Mariano
  • Drosten, Matthias
The transcriptional repressor Capicua (CIC) has emerged as an important rheostat of cell growth regulated by RAS/MAPK signaling. Cic was originally discovered in Drosophila, where it was shown to be inactivated by MAPK signaling downstream of the RTKs Torso and EGFR, which results in signal-dependent responses that are required for normal cell fate specification, proliferation and survival of developing and adult tissues. CIC is highly conserved in mammals, where it is also negatively regulated by MAPK signaling. Here, we review the roles of CIC during mammalian development, tissue homeostasis, tumor formation and therapy resistance. Available data indicate that CIC is involved in multiple biological processes, including lung development, liver homeostasis, autoimmunity and neurobehavioral processes. Moreover, CIC has been shown to be involved in tumor development as a tumor suppressor, both in human as well as in mouse models. Finally, several lines of evidence implicate CIC as a determinant of sensitivity to EGFR and MAPK pathway inhibitors, suggesting that CIC may play a broader role in human cancer than originally anticipated.
Repisalud
Publicación Artículo científico (JournalArticle)

c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling

  • Sanclemente, Manuel
  • Francoz, Sarah
  • Esteban-Burgos, Laura
  • Bousquet-Mur, Emilie
  • Djurec, Magdolna
  • Lopez-Casas, Pedro P
  • Hidalgo, Manuel
  • Guerra, Carmen
  • Drosten, Matthias
  • Musteanu, Mónica
  • Barbacid, Mariano
A quarter of all solid tumors harbor KRAS oncogenes. Yet, no selective drugs have been approved to treat these malignancies. Genetic interrogation of the MAPK pathway revealed that systemic ablation of MEK or ERK kinases in adult mice prevent tumor development but are unacceptably toxic. Here, we demonstrate that ablation of c-RAF expression in advanced tumors driven by KrasG12V/Trp53 mutations leads to significant tumor regression with no detectable appearance of resistance mechanisms. Tumor regression results from massive apoptosis. Importantly, systemic abrogation of c-RAF expression does not inhibit canonical MAPK signaling, hence, resulting in limited toxicities. These results are of significant relevance for the design of therapeutic strategies to treat K-RAS mutant cancers.
Repisalud
Publicación Artículo científico (JournalArticle)

KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors.

  • Paniagua, Guillen
  • Jacob, Harrys K C
  • Brehey, Oksana
  • García-Alonso, Sara
  • Pons, Tirso
  • Musteanu, Mónica
  • Drosten, Matthias
  • Guerra, Carmen
  • Barbacid, Mariano
  • Lechuga, Carmen G
The kinase suppressor of rat sarcoma (RAS) proteins (KSR1 and KSR2) have long been considered as scaffolding proteins required for optimal mitogen-activated protein kinase (MAPK) pathway signalling. However, recent evidence suggests that they play a more complex role within this pathway. Here, we demonstrate that ectopic expression of KSR1 or KSR2 is sufficient to activate the MAPK pathway and to induce cell proliferation in the absence of RAS proteins. In contrast, the ectopic expression of KSR proteins is not sufficient to induce cell proliferation in the absence of either rapidly accelerated fibrosarcoma (RAF) or MAPK-ERK kinase proteins, indicating that they act upstream of RAF. Indeed, KSR1 requires dimerization with at least one member of the RAF family to stimulate proliferation, an event that results in the translocation of the heterodimerized RAF protein to the cell membrane. Mutations in the conserved aspartic acid-phenylalanine-glycine motif of KSR1 that affect ATP binding impair the induction of cell proliferation. We also show that increased expression levels of KSR1 decrease the responsiveness to the KRASG12C inhibitor sotorasib in human cancer cell lines, thus suggesting that increased levels of expression of KSR may make tumour cells less dependent on KRAS oncogenic signalling.
Repisalud
Publicación Artículo científico (JournalArticle)

RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.

  • Sanclemente, Manuel
  • Nieto, Patricia
  • Garcia-Alonso, Sara
  • Fernández-García, Fernando
  • Drosten, Matthias
  • Santamaria, David
  • Musteanu, Mónica
  • Guerra, Carmen
  • Esteban-Burgos, Laura
  • Caleiras, E
  • Martinez Torrecuadrada, Jorge Luis
  • Barbacid, Mariano
  • Caleiras, Eduardo
  • Martinez-Torrecuadrada, Jorge
Repisalud
Publicación Artículo científico (JournalArticle)

Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets

  • Drosten, Matthias
  • Guerra, Carmen
  • Barbacid, Mariano
K-RAS signaling has been intensely studied for over 40 years. Yet, as of today, no drugs have been approved to treat K-RAS mutant cancers. Since the turn of the century, scientists have used genetically engineered mouse (GEM) models to reproduce K-RAS mutant cancers in a laboratory setting to elucidate those molecular events responsible for the onset and progression of these tumors and to identify suitable therapies. In this review, we outline a brief description of available GEM models for two tumor types known to be driven by K-RAS mutations: lung adenocarcinoma and pancreatic ductal adenocarcinoma. In addition, we summarize a series of studies that have used these GEM tumor models to validate, either by genetic or pharmacological approaches, the therapeutic potential of a variety of targets, with the ultimate goal of translating these results to the clinical setting.
Repisalud
Publicación Artículo científico (JournalArticle)

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.

  • Fernández-García, Fernando
  • Fernández-Rodríguez, Ana
  • Fustero-Torre, Coral
  • Piñeiro-Yáñez, Elena
  • Wang, Haiyun
  • Lechuga, Carmen G
  • Callejas, Sergio
  • Álvarez, Rebeca
  • López-García, Alejandra
  • Esteban-Burgos, Laura
  • Salmón, Marina
  • San Román, Marta
  • Guerra, Carmen
  • Ambrogio, Chiara
  • Drosten, Matthias
  • Santamaría, David
  • Al-Shahrour, Fatima
  • Dopazo, Ana
  • Barbacid, Mariano
  • Musteanu, Mónica
Lung cancer is the leading cause of cancer mortality worldwide. KRAS oncogenes are responsible for at least a quarter of lung adenocarcinomas, the main subtype of lung cancer. After four decades of intense research, selective inhibitors of KRAS oncoproteins are finally reaching the clinic. Yet, their effect on overall survival is limited due to the rapid appearance of drug resistance, a likely consequence of the high intratumoral heterogeneity characteristic of these tumors. In this study, we have attempted to identify those functional alterations that result from KRAS oncoprotein expression during the earliest stages of tumor development. Such functional changes are likely to be maintained during the entire process of tumor progression regardless of additional co-occurring mutations. Single-cell RNA sequencing analysis of murine alveolar type 2 cells expressing a resident oncogene revealed impairment of the type I interferon pathway, a feature maintained throughout tumor progression. This alteration was also present in advanced murine and human tumors harboring additional mutations in the p53 or LKB1 tumor suppressors. Restoration of type I interferon (IFN) signaling by IFN-β or constitutive active stimulator of interferon genes (STING) expression had a profound influence on the tumor microenvironment, switching them from immunologically "cold" to immunologically "hot" tumors. Therefore, enhancement of the type I IFN pathway predisposes KRAS mutant lung tumors to immunotherapy treatments, regardless of co-occurring mutations in p53 or LKB1.
Repisalud
Publicación Artículo científico (JournalArticle)

Targeting the MAPK Pathway in KRAS-Driven Tumors.

  • Drosten, Matthias
  • Barbacid, Mariano
KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of KRAS oncoproteins remain undruggable. Here, we review recent efforts to validate individual components of the mitogen-activated protein kinase (MAPK) pathway as targets to treat KRAS-mutant cancers by comparing genetic information derived from experimental mouse models of KRAS-driven lung and pancreatic tumors with the outcome of selective MAPK inhibitors in clinical trials. We also review the potential of RAF1 as a key target to block KRAS-mutant cancers.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer

  • Simón-Carrasco, Lucía
  • Jiménez, Gerardo
  • Jiménez, Gerardo
  • Barbacid, Mariano
  • Drosten, Matthias
The transcriptional repressor Capicua (CIC) has emerged as an important rheostat of cell growth regulated by RAS/MAPK signaling. Cic was originally discovered inDrosophila, where it was shown to be inactivated by MAPK signaling downstream of the RTKs Torso and EGFR, which results in signal-dependent responses that are required for normal cell fate specification, proliferation and survival of developing and adult tissues. CIC is highly conserved in mammals, where it is also negatively regulated by MAPK signaling. Here, we review the roles of CIC during mammalian development, tissue homeostasis, tumor formation and therapy resistance. Available data indicate that CIC is involved in multiple biological processes, including lung development, liver homeostasis, autoimmunity and neurobehavioral processes. Moreover, CIC has been shown to be involved in tumor development as a tumor suppressor, both in human as well as in mouse models. Finally, several lines of evidence implicate CIC as a determinant of sensitivity to EGFR and MAPK pathway inhibitors, suggesting that CIC may play a broader role in human cancer than originally anticipated, This work has been supported by grants from the Fundaci o La Marat ode TV3 (20131730/1) to G.J. and M.B., from the European Research Council (ERC-AG/250297-RAS AHEAD and ERC-AG/695566-THERACAN), the Autonomous Community of Madrid (S2011/BDM-2470/ONCOCYCLE) and the Foundation of the Asociaci on Espa ~ nola contra el C ancer (AECC) (GC16173694BARB) to M.B, and the Spanish Ministry of Economy and Competitiveness (SAF2014-59864-R to M.B. and BFU2014-52863-P to G.J.). M.B. is the recipient of an Endowed Chair from the AXA Research Fund. L.S.C. has been supported by a fellowship from the Programa de Formación de Personal Investigator (FPI) of the Spanish Ministry of Economy and Competitiveness., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors

  • Djurec, Magdolna
  • Graña, Osvaldo
  • Lee, Albert
  • Troulé, Kevin
  • Espinet, Elisa
  • Cabras, Lavinia
  • Navas, Carolina
  • Blasco, María Teresa
  • Martín-Díaz, Laura
  • Burdiel, Miranda
  • Li, Jing
  • Liu, Zhaoqi
  • Vallespinós, Mireia
  • Sánchez-Bueno, Francisco
  • Sprick, Martin R.
  • Trumpp, Andreas
  • Sainz, Bruno Jr.
  • Al-Shahrour, Fátima
  • Rabadán, Raúl
  • Guerra, Carmen
  • Barbacid, Mariano
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the presence of abundant desmoplastic stroma primarily composed of cancer-associated fibroblasts (CAFs). It is generally accepted that CAFs stimulate tumor progression and might be implicated in drug resistance and immunosuppression. Here, we have compared the transcriptional profile of PDGFRα+ CAFs isolated from genetically engineered mouse PDAC tumors with that of normal pancreatic fibroblasts to identify genes potentially implicated in their protumorigenic properties. We report that the most differentially expressed gene, Saa3, a member of the serum amyloid A (SAA) apolipoprotein family, is a key mediator of the protumorigenic activity of PDGFRα+ CAFs. Whereas Saa3-competent CAFs stimulate the growth of tumor cells in an orthotopic model, Saa3-null CAFs inhibit tumor growth. Saa3 also plays a role in the cross talk between CAFs and tumor cells. Ablation of Saa3 in pancreatic tumor cells makes them insensitive to the inhibitory effect of Saa3-null CAFs. As a consequence, germline ablation of Saa3 does not prevent PDAC development in mice. The protumorigenic activity of Saa3 in CAFs is mediated by Mpp6, a member of the palmitoylated membrane protein subfamily of the peripheral membrane-associated guanylate kinases (MAGUK). Finally, we interrogated whether these observations could be translated to a human scenario. Indeed, SAA1, the ortholog of murine Saa3, is overexpressed in human CAFs. Moreover, high levels of SAA1 in the stromal component correlate with worse survival. These findings support the concept that selective inhibition of SAA1 in CAFs may provide potential therapeutic benefit to PDAC patients., This work was supported by European Research Council Grants ERC-AG/250297-RAS AHEAD and ERC-AG/695566-THERACAN, Spanish Ministry of Economy and Competitiveness Grant SAF2014-59864-R, and Asociación Española contra el Cáncer Grant GC16173694BARB (to M. Barbacid). M.D. was supported by a fellowship from La Caixa International Fellowship Program. M. Barbacid is the recipient of an Endowed Chair from the AXA Research Fund.